Functional SARS-CoV-2 cross-reactive CD4 + T cells established in early childhood decline with age

Author:

Humbert Marion12ORCID,Olofsson Anna1,Wullimann David2ORCID,Niessl Julia2ORCID,Hodcroft Emma B.34,Cai Curtis2ORCID,Gao Yu2,Sohlberg Ebba2ORCID,Dyrdak Robert56,Mikaeloff Flora1,Neogi Ujjwal1ORCID,Albert Jan56ORCID,Malmberg Karl-Johan278,Lund-Johansen Fridtjof910ORCID,Aleman Soo1112ORCID,Björkhem-Bergman Linda1314,Jenmalm Maria C.15ORCID,Ljunggren Hans-Gustaf2ORCID,Buggert Marcus2ORCID,Karlsson Annika C.1ORCID

Affiliation:

1. Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, 141 52 Huddinge, Sweden

2. Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, 141 52 Huddinge, Sweden

3. Institute of Social and Preventive Medicine, University of Bern, Bern 3012, Switzerland

4. Swiss Institute of Bioinformatics, Lausanne 1015, Switzerland

5. Department of Clinical Microbiology, Karolinska University Hospital, 171 76 Stockholm, Sweden

6. Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden

7. Department of Cancer Immunology, Institute for Cancer Research, University of Oslo, 0379 Oslo, Norway

8. Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, 0379 Oslo, Norway

9. Department of Immunology, Institute of Clinical Medicine, Oslo University Hospital, 0372 Oslo, Norway

10. ImmunoLingo Convergence Center, Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway

11. Unit for Infectious Diseases and Dermatology, I73, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden

12. Infectious Diseases and Dermatology Unit, Department of Medicine, Huddinge, Karolinska Institutet, 141 86 Huddinge, Sweden

13. Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 141 83 Huddinge, Sweden

14. Palliative Medicine, Stockholms Sjukhem, 112 19 Stockholm, Sweden

15. Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Linköping University, 581 83 Linköping, Sweden

Abstract

Pre-existing SARS-CoV-2-reactive T cells have been identified in SARS-CoV-2-unexposed individuals, potentially modulating COVID-19 and vaccination outcomes. Here, we provide evidence that functional cross-reactive memory CD4 + T cell immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is established in early childhood, mirroring early seroconversion with seasonal human coronavirus OC43. Humoral and cellular immune responses against OC43 and SARS-CoV-2 were assessed in SARS-CoV-2-unexposed children (paired samples at age two and six) and adults (age 26 to 83). Pre-existing SARS-CoV-2-reactive CD4 + T cell responses targeting spike, nucleocapsid, and membrane were closely linked to the frequency of OC43-specific memory CD4 + T cells in childhood. The functional quality of the cross-reactive memory CD4 + T cell responses targeting SARS-CoV-2 spike, but not nucleocapsid, paralleled OC43-specific T cell responses. OC43-specific antibodies were prevalent already at age two. However, they did not increase further with age, contrasting with the antibody magnitudes against HKU1 (β-coronavirus), 229E and NL63 (α-coronaviruses), rhinovirus, Epstein–Barr virus (EBV), and influenza virus, which increased after age two. The quality of the memory CD4 + T cell responses peaked at age six and subsequently declined with age, with diminished expression of interferon (IFN)-γ, interleukin (IL)-2, tumor necrosis factor (TNF), and CD38 in late adulthood. Age-dependent qualitative differences in the pre-existing SARS-CoV-2-reactive T cell responses may reflect the ability of the host to control coronavirus infections and respond to vaccination.

Funder

European Molecular Biology Organization

The Swedish Research Council

Stockholm läns landsting

Cancerfonden

Knut och Alice Wallenbergs Stiftelse

Swedish Research Council

EC | European Research Council

Karolinska Institutet

Swedish Childhood Cancer Fund

Åke Wibergs Stiftelse

Centrum for Innovative Medicine (CIMED) project grant, senior

Swiss National Science Foundation

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3